IS6616A - Setnar bísýklískar afleiður til meðhöndlunar á afbrigðilegum frumuvexti - Google Patents
Setnar bísýklískar afleiður til meðhöndlunar á afbrigðilegum frumuvextiInfo
- Publication number
- IS6616A IS6616A IS6616A IS6616A IS6616A IS 6616 A IS6616 A IS 6616A IS 6616 A IS6616 A IS 6616A IS 6616 A IS6616 A IS 6616A IS 6616 A IS6616 A IS 6616A
- Authority
- IS
- Iceland
- Prior art keywords
- treatment
- cell growth
- aberrant cell
- bicyclic derivatives
- bicyclic
- Prior art date
Links
- 230000001594 aberrant effect Effects 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21313600P | 2000-06-22 | 2000-06-22 | |
| PCT/IB2001/001046 WO2001098277A2 (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6616A true IS6616A (is) | 2002-11-14 |
Family
ID=22793862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6616A IS6616A (is) | 2000-06-22 | 2002-11-14 | Setnar bísýklískar afleiður til meðhöndlunar á afbrigðilegum frumuvexti |
Country Status (42)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| EP1117653B1 (en) | 1998-10-01 | 2003-02-05 | AstraZeneca AB | Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |
| AU2001264159A1 (en) * | 2000-06-22 | 2002-01-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| DE60237145D1 (de) * | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
| US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
| CA2462149C (en) * | 2001-11-30 | 2010-06-22 | Pfizer Products Inc. | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| EA007412B1 (ru) * | 2001-12-12 | 2006-10-27 | Пфайзер Продактс Инк. | Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака |
| EP1465632A1 (en) * | 2001-12-12 | 2004-10-13 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| AU2003291394B2 (en) | 2002-11-20 | 2009-06-25 | Array Biopharma, Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| PL377686A1 (pl) * | 2002-12-18 | 2006-02-06 | Pfizer Products Inc. | Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek |
| CA2509140A1 (en) * | 2002-12-19 | 2004-07-08 | Pfizer Products Inc. | Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
| RU2005125607A (ru) * | 2003-04-09 | 2006-03-27 | Пфайзер Продактс Инк. (Us) | Способы получения производных n(пиридинилокси)-фениламино)хиназолинил)аллил)ацетамида и родственных соединений, а также промежуточные соединения для таких способов и способы получения таких соединений |
| MXPA05012839A (es) * | 2003-05-27 | 2006-05-17 | Pfizer Prod Inc | Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa. |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| NZ544472A (en) * | 2003-07-03 | 2009-04-30 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
| JP2007533596A (ja) * | 2003-07-15 | 2007-11-22 | ナショナル・リサーチ・カウンシル・オブ・カナダ | 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| CA2535614C (en) * | 2003-08-14 | 2009-12-22 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| CN1838959A (zh) * | 2003-08-18 | 2006-09-27 | 辉瑞产品公司 | Erbb2抗癌剂的给药方案 |
| BRPI0414489A8 (pt) | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| ES2436888T3 (es) * | 2003-09-26 | 2014-01-07 | Exelixis, Inc | Moduladores c-Met y métodos de uso |
| JP2007510708A (ja) * | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| US7632840B2 (en) | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| EP1802341A1 (en) | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| JPWO2006025490A1 (ja) * | 2004-09-01 | 2008-05-08 | 田辺三菱製薬株式会社 | 分子シャペロン機能調節剤 |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| UA95775C2 (uk) | 2005-04-26 | 2011-09-12 | Пфайзер Инк. | Антитіло, яке специфічно зв'язується з р-кадгерином |
| US20080194596A1 (en) * | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| AP2013006963A0 (en) | 2005-09-07 | 2013-07-31 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like Kinase-1 |
| KR101086967B1 (ko) | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| MEP43308A (en) | 2006-05-09 | 2011-02-10 | Pfizer Prod Inc | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG174774A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| US20080221132A1 (en) * | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| RU2009126576A (ru) | 2006-12-12 | 2011-01-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Конденсированное гетероциклическое соединение |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| EP2851091B1 (en) | 2007-04-13 | 2017-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to ERBB therapeutics |
| EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TW200944528A (en) | 2008-03-12 | 2009-11-01 | Takeda Pharmaceutical | Fused heterocyclic compound |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| EP2387563B2 (en) | 2009-01-16 | 2022-04-27 | Exelixis, Inc. | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CA2813162C (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
| BR112014006840A2 (pt) | 2011-09-22 | 2017-04-04 | Pfizer | derivados de pirrolopirimidina e purina |
| CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| PE20161436A1 (es) | 2014-04-30 | 2017-01-08 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| JP6791979B2 (ja) * | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP7483193B2 (ja) | 2018-06-13 | 2024-05-15 | カリフォルニア・インスティテュート・オブ・テクノロジー | 血脳バリアを越えるためのナノ粒子とそれを用いた治療法 |
| LT3853220T (lt) | 2018-09-18 | 2024-03-12 | F. Hoffmann-La Roche Ag | Chinazolino dariniai kaip antinavikiniai preparatai |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
| TW202530231A (zh) * | 2023-09-27 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹唑啉衍生物的可藥用鹽、其結晶形式及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW321649B (cg-RX-API-DMAC7.html) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| PT1119567E (pt) | 1998-10-08 | 2005-08-31 | Astrazeneca Ab | Derivados de quinazolina |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| AU2001264159A1 (en) * | 2000-06-22 | 2002-01-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
-
2001
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en not_active Ceased
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active Expired - Fee Related
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166D0/no unknown
-
2005
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6616A (is) | Setnar bísýklískar afleiður til meðhöndlunar á afbrigðilegum frumuvexti | |
| IS7233A (is) | Kínasólín afleiður til meðhöndlunar á afbrigðilegum frumuvexti | |
| IS2223B (is) | Aðferð til framleiðslu á 5-sýanóþalíði | |
| DK1147083T3 (da) | Arylpiperazinyl-cyclohexylindolderivater til behandling af depression | |
| IS6286A (is) | Efnasambönd til meðhöndlunar á blóðþurrð | |
| IS6785A (is) | EP4 viðtakahindrar til meðhöndlunar á liðagigt | |
| DK1144395T3 (da) | 2-amino-benzoxazinon-derivater til behandling af fedme | |
| NO20015156D0 (no) | 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse | |
| DK1292594T3 (da) | Quinazolinderivater til behandling af tumorer | |
| DK1218382T3 (da) | Bicykliske imidazo-3-ylaminderivater | |
| DE60025598D1 (de) | Zweikammerabgabebehälter | |
| DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
| NO20022087D0 (no) | Fremgangsmåte for behandling av diabetes | |
| NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| IS5952A (is) | Aðferð til framleiðslu á 5-sýanóþalíði | |
| IS5715A (is) | Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni | |
| DE50015443D1 (de) | Bicyclische imidazo-5-yl-aminderivate | |
| NO20024776L (no) | Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte | |
| NO20024777L (no) | Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte | |
| IS6098A (is) | Ósantant til meðhöndlunar á skaptruflunum | |
| IS6020A (is) | S-nítrósóþíól til meðferðar við blóðrásartruflunum | |
| DK1226125T3 (da) | Fremgangsmåde til fremstilling af mavesårsmidler | |
| NO20020328D0 (no) | Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol | |
| NO20042542L (no) | Anvendelse av ascomycin for behandling av blefarit | |
| IS5212A (is) | Bætt aðferð til framleiðslu á pýrazólópýrimidínónafleiðu |